TY - JOUR
T1 - Hot Topic
T2 - Precision Medicine for Asthma—Has the Time Come?
AU - Li, Xingnan
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Purpose of Review: Asthma is a common inflammatory airway disease, which affects more than 300 million people worldwide. Although conventional drugs are effective for most of the patients with mild-to-moderate asthma, they are less effective for patients with difficult-to-treat or severe asthma. Identification of asthma endotypes and biomarkers will lead to more precise approaches to treat asthma. Recent Findings: Asthma subphenotypes and endotypes have been described based on clinical variables and sputum granulocytes. A recent asthma endotype study has been summarized based on the combination of T2 (FeNO) and non-T2 (IL-6) biomarkers. Discovery of potential biomarkers for asthma has been discussed in the context of omics approaches. Current biologic drugs for asthma have been summarized, and the future direction of precise treatment of asthma has been suggested. Summary: This review provides a concise overview of the current state of subphenotypes, endotypes, biomarkers, omics approaches, and biologic drugs in asthma.
AB - Purpose of Review: Asthma is a common inflammatory airway disease, which affects more than 300 million people worldwide. Although conventional drugs are effective for most of the patients with mild-to-moderate asthma, they are less effective for patients with difficult-to-treat or severe asthma. Identification of asthma endotypes and biomarkers will lead to more precise approaches to treat asthma. Recent Findings: Asthma subphenotypes and endotypes have been described based on clinical variables and sputum granulocytes. A recent asthma endotype study has been summarized based on the combination of T2 (FeNO) and non-T2 (IL-6) biomarkers. Discovery of potential biomarkers for asthma has been discussed in the context of omics approaches. Current biologic drugs for asthma have been summarized, and the future direction of precise treatment of asthma has been suggested. Summary: This review provides a concise overview of the current state of subphenotypes, endotypes, biomarkers, omics approaches, and biologic drugs in asthma.
KW - Asthma
KW - Biomarker
KW - Endotype
KW - Omics
KW - Precision medicine
KW - Subphenotype
UR - http://www.scopus.com/inward/record.url?scp=85071747018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071747018&partnerID=8YFLogxK
U2 - 10.1007/s11882-019-0881-3
DO - 10.1007/s11882-019-0881-3
M3 - Review article
C2 - 31486903
AN - SCOPUS:85071747018
SN - 1529-7322
VL - 19
JO - Current Allergy and Asthma Reports
JF - Current Allergy and Asthma Reports
IS - 10
M1 - 45
ER -